Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose vs Standard-dose Short-course Radiotherapy + CAPOX + Sintilimab + IL-2 in Locally Advanced Rectal Cancer
NCT07646639Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- May 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, aldesleukin, capecitabine, oxaliplatin in rectal cancer, sponsored by Jiangsu Provincial People's Hospital. Started May 2026; status: recruiting.
02
Drugs
sintilimabaldesleukincapecitabineoxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07646639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07646639.